Skip to main content
Premium Trial:

Request an Annual Quote

Oligo Manufacturer DNA Script Raises $38.5M in Series B Round

NEW YORK (GenomeWeb) — French nucleic acid manufacturer DNA Script said today that it has closed an oversubscribed Series B round, raising $38.5 million.

The round was led by healthcare investment firm LSP and included French government investment bank Bpifrance. Also joining the round were existing investors Illumina Ventures, M Ventures, Sofinnova Partners, Kurma Partners, and Idinvest Partners.

DNA Script said it will use the funding to accelerate the development of products based on its proprietary de novo nucleic acid synthesis technology, which relies on modified nucleotides and enzymes. The company has been planning to roll out an early-access program for its platform by the end of this year.

DNA Script said it also intends to use the financing to hire product development and commercialization staffers in the US, where it recently established a subsidiary, and to bring on additional researchers in France.

"In less than two years since our last financing round … DNA Script [has become] the first company to enzymatically synthesize a 200-mer oligo de novo with an average coupling efficiency that rivals the best organic chemical processes in use today," DNA Script Cofounder and CEO Thomas Ybert said in a statement. "Our technology is now reliable enough for its first commercial applications, which we believe will deliver the promise of same-day results to researchers everywhere, with DNA synthesis that can be completed in just a few hours."

In 2017, DNA Script raised €11 million ($12.3 million) in a Series A financing round. About a year ago, it was awarded $5.5 million in grant funding from the European Commission and Bpifrance.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.